Wordt geladen...
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
BACKGROUND: Trabectedin has recently been approved in the USA and in Europe for advanced soft-tissue sarcoma patients who have been treated with anthracycline-based chemotherapy without success. The mechanism of action of trabectedin depends on the status of both the nucleotide excision repair (NER)...
Bewaard in:
| Gepubliceerd in: | J Hematol Oncol |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5387279/ https://ncbi.nlm.nih.gov/pubmed/28399901 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0451-x |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|